Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives, Dan Lynch, and ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...

BMY gears up for Q2 results as growth drugs partially offset legacy declines, cost cuts kick in and new launches gain ...

Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 ...

The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

The tricky part is that it isn't always easy to find companies you can buy and hold. The corporate landscape is ruthlessly ...

BMY rises 6.3% in a month as investors pin hopes on new drugs to offset pressure from pipeline and patent losses.

Princeton: Bristol Myers Squibb and Bain Capital have announced the formation of a new independent biopharmaceutical company, ...

Bristol Myers Squibb (BMY) and Bain Capital have announced the formation of a new independent biopharmaceutical company dedicated to developing innovative therapies for ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Piper Sandler lowered the firm’s price target on Bristol Myers (BMY) to $64 from $66 and keeps an Overweight rating on the shares ahead of ...